ELVR · Elevra Lithium

The thesis

Elevra Lithium's operating results improved in the September quarter, and the shares have started to respond: they closed at $27.85 on 11 November 2026, up from $24.62 the session before and from the 52-week closing low of $21.96 on 30 October 2026. The December-quarter report, expected around 27 January 2027, settles the final price on the quarter's shipments and shows whether sales stay at or above production.

The 27 October 2026 quarterly report showed sales of 58,134 dry metric tonnes (dmt) against production of 54,907 dmt, a unit operating cost of US$780 per dmt sold, and net cash of US$240 million at 30 September 2026. The Ewoyaa sale to Zhejiang Huayou Cobalt completed on 26 October 2026. The shares remain well below their earlier levels: the 3-month price change is −56.1% (adjusted daily closes) and the last close is 72.9% below the 52-week intraday high of $102.80 set on 15 June 2026.

Bullish and bearish views on Elevra Lithium Limited

The bull case on Elevra Lithium Limited (ELVR), in brief: sales caught up with production. The bear case: the shares fell after a good report.

Bull case

• Sales caught up with production. Elevra's Q1 FY27 report (27 October 2026) shows sales of 58,134 dmt, up 71% on the June quarter, against production of 54,907 dmt at a 5.1% grade. FY26 sales had trailed production, at 181,494 dmt against 197,967 dmt.
• Realised price rose sharply. Elevra estimated US$1,276 per dmt FOB (free on board), or US$1,524 per dmt on a 6%-grade equivalent, from 30 September spot indices (report of 27 October 2026).
• Costs fell below guidance. Unit operating cost was US$780 per dmt sold, down 14% from US$907 in the June quarter (Elevra, 27 October 2026). FY27 guidance issued on 28 August 2026 was US$880–950 per dmt.
• Cash position is strong. Elevra reported US$319 million of cash and US$240 million of net cash at 30 September 2026, before about US$71 million in cash from the Ewoyaa sale that completed on 26 October 2026.
• Expansion is funded and a buyer is named. The pre-feasibility study lifts annual output from about 199,000 tonnes to 373,000 tonnes at life-of-mine C1 costs of US$630 per tonne, and Elevra says the project is funded. The binding LG Energy Solution contract covers 240,000 dmt through 2029 at market-linked prices (Mining Weekly, 8 October 2026).
• An officer bought shares. Chief Financial Officer Christian Cortes Vargas bought 16,000 shares at $2.67 on 28 October 2026 (SEC Form 4, filed 29 October 2026).

Bear case

• The shares fell after a good report. The close was $25.12 on 22 October 2026 before the report and $24.26 on 6 November 2026 after it, against $33.61 on 9 October 2026. Better sales, prices and costs did not lift the shares until the 11 November 2026 session.
• The realised price is provisional. The US$1,276 per dmt figure rests on spot indices at 30 September 2026 and settles in the December quarter. A lower spodumene price by then would cut it.
• Group cash flow is not shown. The report gives North American Lithium (NAL) net operating cash inflow of US$34 million but no group figure. FY26 group operating cash flow was an outflow of US$44 million against net profit of US$44 million, which included a US$156 million impairment reversal (FY26 results, 28 August 2026).
• Safety record weakened. Elevra reported six recordable injuries in the September quarter while hours worked rose 20% with expansion activity (report of 27 October 2026).
• An officer sold after exercising options. Group Chief Operating Officer Sylvain Collard exercised options over 52,075 shares on 31 October 2026 and sold 32,651 shares at $2.15 on 2 November 2026 (SEC Form 4, filed 3 November 2026).
• The board is shrinking. Non-executive directors Allan Buckler and Jorge Beristain resign at the close of the 19 November 2026 annual general meeting, cutting the board from eight to six (Elevra, 27 October 2026).

Price setup

The close was $27.85 on 11 November 2026, after $24.62 on 10 November 2026, $25.73 on 9 November 2026, $24.26 on 6 November 2026, $24.24 on 5 November 2026 and $22.63 on 4 November 2026. No company news explains the 11 November 2026 move; the latest company release is the 6 November 2026 NAL expansion targets announcement.

The shares trade below both the 50-day moving average of $36.04 and the 200-day moving average of $58.77 (adjusted daily closes, as of 11 November 2026). The $33.61 close of 9 October 2026, the day after the LG contract was reported, is the nearest reference above the market. The 52-week closing low of $21.96 on 30 October 2026 is the nearest reference below it.

The market has priced in a large part of the lithium-price and earnings downside: the 3-month change is −56.1% from the $63.46 close of 13 August 2026, even though Elevra's September-quarter results showed higher sales, a higher estimated realised price and lower costs.

Catalysts ahead

• 19 November 2026: Elevra 2026 annual general meeting; two non-executive directors resign at its close. Governance event that cuts the board from eight to six directors; it adds no operating information.
• ~27 January 2027 (est.): December-quarter FY27 activities report. Settles the final price on September-quarter shipments and shows whether sales stay at or above production.

What would change the view

A daily close below $22.00, which would retest the 52-week closing low of $21.96 set on 30 October 2026 and show the market rejecting the improvement. A December-quarter report with sales again below production would also break the case.

The risks this note tracks, each with what would confirm it:

• The US$1,276 per dmt realised price is provisional and could settle lower if spodumene prices fall. Confirmed by: the December-quarter report shows final pricing on September-quarter shipments materially below the estimate.
• Cash conversion remains weak at group level despite higher prices. Confirmed by: the half-year accounts show group operating cash outflow while NAL reports an inflow.
• Safety incidents or construction disruption interrupt mining and the expansion. Confirmed by: Elevra reports a further rise in recordable injuries, a work stoppage or an expansion delay.
• Sales fall back below production, reversing the inventory catch-up seen in the September quarter. Confirmed by: the December-quarter report shows sales below production for a second time in FY27 or growing concentrate stockpiles.

What it trades with

Elevra trades on lithium prices and the spodumene concentrate market more than on the broader US equity market. With the Ewoyaa sale closed, the Huayou transaction no longer sits between Elevra and Atlantic Lithium as a swing factor. Elevra still holds 32,517,598 Atlantic Lithium shares, about 4.1% of that company (Elevra update, 1 October 2026).